Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | ALPI | P09923 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31708812 | 0.88 | CHRM3 (0.35) | CHRM3ALDH1A1NPC1RAB9AALPL | |
| SCHEMBL31708859 | 0.86 | CHRM3 (0.43) | CHRM3ALDH1A1KDM4E | |
| SCHEMBL31709174 | 0.82 | CHRM3 (0.46) | CHRM3ALDH1A1POLBGAAKDM4E | |
| SCHEMBL27140995 | 0.81 | KDM4E (0.38) | CHRM3ALDH1A1GAAKDM4ETDP1 | |
| SCHEMBL27140992 | 0.81 | KDM4E (0.38) | CHRM3ALDH1A1GAAKDM4ETDP1 | |
| SCHEMBL31709210 | 0.79 | MAPT (0.52) | CHRM3ALDH1A1POLBGAAKDM4E | |
| SCHEMBL31709126 | 0.77 | CHRM3 (0.44) | CHRM3 | |
| Bromide SCHEMBL31464137 | 0.76 | CHRM3 (0.44) | CHRM3 | |
| SCHEMBL31709129 | 0.76 | ALDH1A1 (0.39) | CHRM3ALDH1A1POLBKDM4ETDP1 | |
| SCHEMBL31708764 | 0.75 | HTR2A (0.47) | CHRM3ALDH1A1POLBGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | CHRM3 4846/4885ALDH1A1 774/4885NPC1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.